Olympus reviewed the following literature titled "efficacy and safety of endoscopic submucosal dissection for superficial gastric neoplasms: a latin american cohort study" background/aims: endoscopic submucosal dissection (esd) is the preferred technique for treating early gastric cancer (egc).However, very few studies have been conducted in south america.This study aimed to assess the efficacy and safety of esd for egc.Methods: we analyzed data from a prospective cohort from 2013 to 2020.A total of 152 superficial gastric neoplasms that fulfilled the absolute or expanded criteria for esd were included.Outcomes were en bloc, r0, and curative resection rates, incidence of adverse events, and length of procedure.Results: the age of the enrolled patients was 68.4±11.3 years.The number of included patients based on the absolute and expanded indications was 150 and 2, respectively.En bloc, r0, and curative resections were achieved in 98.0%, 96.1%, and 89.5% of the cases, respectively.Bleeding and perforation were reported in 5.9% and 6.6% of the cases, respectively.Histopathological examination revealed low-grade dysplasia, high-grade dysplasia, well-differentiated adenocarcinoma, and poorly differentiated adenocarcinoma in 13, 20, 117, and 2 cases, respectively.Conclusions: our study shows that esd performed by properly trained endoscopists in reference centers is safe and effective, with comparable therapeutic outcomes to those reported in the eastern series.Type of adverse events/number of patients: immediate perforation - 9 patients.Delayed perforation - 1 patient.Intraprocedural bleeding - 3 patients.Delayed bleeding - 6 patients.This literature article requires 4 reports.The related patient identifiers are as follows: (b)(6).This medwatch report is for patient identifier (b)(6).There is no report of any olympus device malfunction in any procedure described in this study.
|
This report is being supplemented to provide additional information based on the legal manufacturer's final investigation.The device history record was unable to be reviewed for this device since the serial and/or lot number was not provided.However, olympus only releases products to market that meet all manufacturing specifications and final product release criteria.Based on the results of the investigation, the relationship between the device and the adverse event cannot be confirmed.There was no complaint reported on the subject device.There is no evidence of an olympus device malfunction.Therefore, the root cause cannot be determined.This supplemental report includes a correction to e4 to provide information that was inadvertently not included on the initial medwatch.Olympus will continue to monitor field performance for this device.
|